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Laboratory for Epigenetics and Environment, Centre National de Génotypage, CEA-Institut de Génomique, 2 rue Gaston Crémieux, CP5721, 91000 Evry, FranceAlteration of DNA methylation patterns at the 5′ position of
cytosines, in the context of CpG dinucleotides, is one of the most
promising epigenetic biomarkers for many biomedical applications
and has been actively studied in many diseases and developmental
questions for the last twenty years (How Kit et al., 2012). In comparison
to genetic alterations such as mutations, which are usually distributed
throughout the gene, DNA methylation alterations are concentrated
in a deﬁned area, often the promoter, facilitating analysis. DNA
methylation can be reliably analyzed in freshly frozen and archived
clinical specimens, but more importantly, also in bioﬂuids, that were
either in direct contact with the disease (e.g. stool for colorectal, urine
for genitourinary or sputum, bronchoalveolar lavages or brushes for
lung cancer) or in cell-free circulating DNA isolated from serum or
plasma of patients (How Kit et al., 2012).
Although it is currently unclear if DNA methylation changes are the
cause or the consequence of the disease, it is clear that DNAmethylation
changes occur early during disease pathogenesis and precede disease
detection by histological and/or imaging methods. Several DNA
methylation-based biomarkers are already commonly used in the clinic,
such as the testing of the DNAmethylation status of theMGMT promot-
er for the prediction of the response to chemotherapy using alkylating
agents in glioblastoma or ofMLH1 for the diagnosis of Lynch Syndrome.
Commercial products such as the Epi proColon test, analyzing methyla-
tion in the SEPT9 gene (Church et al., 2014) for the population-wide
screening for colorectal cancer and approved by the Chinese FDA in
July 2015, and the Epi proLung (SHOX2) test (Ilse et al., 2014) are now
available. Panelswithmultiple genes can further improve the speciﬁcity
and sensitivity of DNAmethylation signatures as recently demonstrated
in a stool-based screening test for colorectal cancer ((Imperiale et al.,
2014), Cologuard, Exact Sciences), where DNA methylation alterations
were combined with mutation detection and which received the ﬁrst
US-FDA approval for a DNA methylation-based diagnostic test in 2014.
Lung cancer is the most common cancer in the world and few
effective and cheap methods are available for its early detection and
screening, especially in at-risk populations such as heavy smokers or
patients with chronic obstructive lung disease (COPD) and ﬁbrotic
interstitial lung diseases (ILDs). Although histological and cytological
examinations are currently the gold standard in lung cancer diagnosis,
patients are often at late stages when diagnosis is conﬁrmed. Therefore,DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.06.025.
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early diagnostic rate, enhance the conﬁrmed diagnostic rate, monitor
potential disease progression to lung cancer in high-risk populations,
and improve the differentiation of lung cancer from other lung diseases
to avoid overtreatment of patients.
While epigenetic changes are well characterized in lung cancer
(Liloglou et al., 2014), our understanding of epigenetic changes in
COPD and ILD is still in its infancy, and DNA methylation changes that
might be of potential therapeutic importance have been identiﬁed
(Kabesch and Adcock, 2012; Hagood, 2014). Furthermore, smoking
has shown in several epigenome-wide association studies to yield
highly reproducible DNA methylation changes at speciﬁc loci such as
F2RL3 and ARHH that could contribute to the health risks associated
with smoking (Zeilinger et al., 2013).
In the current issue, Wielscher et al. (2015) develop a four gene
DNA methylation signature for the detection of lung cancer and its
differentiation from other lung diseases with a high risk of cancer
development, such as COPD and ILD, in retrospective cohorts and
provide a paradigm for the development of DNA methylation-based
diagnostic assays. They translate ﬁndings in the tissue to a potential
diagnostic test in cell-free circulating DNA that can be easily obtained
with minimally invasive procedures. The study distinguishes itself
positively from the many so called “biomarker” studies using DNA
methylation alterations by the use of relatively large cohorts and an
analysis strategy based on solid and appropriate statistics.
Starting from a genome-wide screen of DNA from 129 lung tissues
with the widely used Illumina 450K BeadChip, the authors identify a
panel of 222 DNA methylation-based markers that distinguish either
the different disease groups or any disease from healthy tissue. Using
a technology that can potentially be easily transferred into a clinical
laboratory (digestion with a methylation-sensitive restriction enzyme
followed by multiplexed real-time PCR ampliﬁcation), a panel of 63
multiplex PCR assays was devised and the DNA methylation patterns
were analyzed in 204 sera/plasma yielding a high AUC of 0.91 for lung
cancer and slightly less for ILD and COPD. Reducing the signature to a
clinically more easily manageable size of four genes with two genes
accounting for disease status versus healthy and two genes speciﬁc for
lung cancer still correctly identiﬁed most cancer samples (22/23) in
an independent validation cohort, but also yielded some more false
positive results, which in clinical practice would be more acceptable
than false negative results. Although the potential value of the signature
for prospective studies was assessed through predictive modeling,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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progressing to lung cancer, will be required to assess the clinical
value of the presented signature.
While this study is of high quality and analyzes a larger number
of samples than most DNA methylation studies, the large number of
histologic subgroups together with their subclassiﬁcation such as
TNM for lung cancer and GOLD for COPD makes the validation in
multi-centric international collaborations for larger cohorts necessary,
potentially going back to a larger gene panel to optimize sensitivity
and speciﬁcity. Furthermore, it will be important to combine and
compare the signature developed by Wielscher et al. (2015) with DNA
methylation markers including SHOX2 (Ilse et al., 2014) and other pre-
viously reported markers (Liloglou et al., 2014) as well as signatures
that have been developed for the early detection and prognosis of
lung cancer (Sandoval et al., 2013). Finally, as for other DNA methyla-
tionmarkers and signatures it will be necessary to assess the speciﬁcity
of the signature by analyzing the DNA methylation changes in other
solid tumors at the loci included in the signature.
The presented work is a ﬁrst major step potentially allowing the
detection of lung cancer at early stages, and more importantly the
monitoring of at-risk populations for progression into lung cancer.
The workﬂow presented in the study should be an example forfuture DNA methylation based biomarker studies. However, extensive
validation and replication will be required to assess fully its clinical
value and utility.
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